Comments on Glintborg et al.'s drug-drug interactions study (EJCP 2005; 61

675-681)

Mark Naunton, Michiel Duyvendak, Gregory M. Peterson, Jacobus R J B Brouwers

Research output: Contribution to journalLetter

1 Citation (Scopus)

Abstract

The results from the recent study by Glintborg et al. [1] are not surprising (lack of significant drug-drug interactions in patients recently discharged from hospital). It is expected that clinically important interactions are identified while the patient is in hospital, with one of the offending agents stopped or changed to a safer alternative before discharge. Furthermore, any clinically important interactions are likely to be identified by the patient’s community pharmacist, who alerts the general practitioner and prevents possible harm before the prescription is even dispensed.
Original languageEnglish
Pages (from-to)159-160
Number of pages2
JournalEuropean Journal of Clinical Pharmacology
Volume62
Issue number2
DOIs
Publication statusPublished - 1 Feb 2006
Externally publishedYes

Fingerprint

Drug Interactions
Pharmaceutical Preparations
Pharmacists
General Practitioners
Prescriptions

Cite this

Naunton, Mark ; Duyvendak, Michiel ; Peterson, Gregory M. ; Brouwers, Jacobus R J B. / Comments on Glintborg et al.'s drug-drug interactions study (EJCP 2005; 61 : 675-681). In: European Journal of Clinical Pharmacology. 2006 ; Vol. 62, No. 2. pp. 159-160.
@article{6100b11e38b449f9a3b3c47f79022509,
title = "Comments on Glintborg et al.'s drug-drug interactions study (EJCP 2005; 61: 675-681)",
abstract = "The results from the recent study by Glintborg et al. [1] are not surprising (lack of significant drug-drug interactions in patients recently discharged from hospital). It is expected that clinically important interactions are identified while the patient is in hospital, with one of the offending agents stopped or changed to a safer alternative before discharge. Furthermore, any clinically important interactions are likely to be identified by the patient’s community pharmacist, who alerts the general practitioner and prevents possible harm before the prescription is even dispensed.",
author = "Mark Naunton and Michiel Duyvendak and Peterson, {Gregory M.} and Brouwers, {Jacobus R J B}",
year = "2006",
month = "2",
day = "1",
doi = "10.1007/s00228-005-0074-y",
language = "English",
volume = "62",
pages = "159--160",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "2",

}

Comments on Glintborg et al.'s drug-drug interactions study (EJCP 2005; 61 : 675-681). / Naunton, Mark; Duyvendak, Michiel; Peterson, Gregory M.; Brouwers, Jacobus R J B.

In: European Journal of Clinical Pharmacology, Vol. 62, No. 2, 01.02.2006, p. 159-160.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Comments on Glintborg et al.'s drug-drug interactions study (EJCP 2005; 61

T2 - 675-681)

AU - Naunton, Mark

AU - Duyvendak, Michiel

AU - Peterson, Gregory M.

AU - Brouwers, Jacobus R J B

PY - 2006/2/1

Y1 - 2006/2/1

N2 - The results from the recent study by Glintborg et al. [1] are not surprising (lack of significant drug-drug interactions in patients recently discharged from hospital). It is expected that clinically important interactions are identified while the patient is in hospital, with one of the offending agents stopped or changed to a safer alternative before discharge. Furthermore, any clinically important interactions are likely to be identified by the patient’s community pharmacist, who alerts the general practitioner and prevents possible harm before the prescription is even dispensed.

AB - The results from the recent study by Glintborg et al. [1] are not surprising (lack of significant drug-drug interactions in patients recently discharged from hospital). It is expected that clinically important interactions are identified while the patient is in hospital, with one of the offending agents stopped or changed to a safer alternative before discharge. Furthermore, any clinically important interactions are likely to be identified by the patient’s community pharmacist, who alerts the general practitioner and prevents possible harm before the prescription is even dispensed.

UR - http://www.scopus.com/inward/record.url?scp=33645419766&partnerID=8YFLogxK

U2 - 10.1007/s00228-005-0074-y

DO - 10.1007/s00228-005-0074-y

M3 - Letter

VL - 62

SP - 159

EP - 160

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 2

ER -